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Like SARS coronavirus (SARS-CoV), the new coronavirus (SARS-CoV2), which is 
causing the epidemic COVID-19, enters human cells by binding to angiotensin-
converting enzyme-2 (ACE2) although with a higher affinity (1).  Once attached to 
ACE2, the viral spike protein is primed by the host serine protease TMPRSS2, which 
ultimately allows fusion of viral and cellular membranes. 
 
ACE2 is a key protein of the protective branch of the renin-angiotensin system, which 
converts angiotensin (Ang) II, the main biologically active peptide of the RAS, into its 
physiological antagonist Ang-(1-7). ACE2 also metabolizes Ang I into Ang-(1-9), which 
is then converted into Ang-(1-7) by angiotensin-converting enzyme (ACE). Ang-(1-7) 
opposes the vasoconstrictor, pro-inflammatory, pro-oxidant, pro-proliferative or pro-
fibrotic actions exerted by Ang II via AT1 receptors (Figure 1).  
 
The binding of SARS-CoV to the ACE2 catalytic site downregulates the expression of 
ACE2 leading to increases in Ang II (1). ACE2 is expressed in many organs, but is 
particularly abundant in alveolar epithelial cells and lung endothelial cells (2). This would 
explain why the lung is especially vulnerable to SARS-CoV2. Indeed, the lethality of 
SARS-CoV has been shown to be dependent on the loss of key regulatory factors in the 
lung related to the down-regulation of ACE2 (3). 
 
Ang-(1-7) seems to be critical in protecting against lung inflammation and fibrosis. This 
heptapeptide inhibits alveolar cell apoptosis, attenuates endothelial cell activation and the 
loss of barrier function and oedema, and limits the synthesis of pro-inflammatory and 
pro-fibrotic cytokines. This is particularly relevant since both acute lung injury and acute 
respiratory distress syndrome (ARDS) are accompanied by a cytokine storm and an 
overwhelming inflammatory response (2). Indeed, activated endothelial cells are 
increasingly recognized as main orchestrators of the inflammatory response in ARDS. 
 
Hypertension is a comorbidity that may exacerbate the severity of SARS-CoV2 infection 
(4). The underlying mechanisms are not clear, but the antihypertensive drugs such as AT1 
receptor blockers (ARB) or ACE inhibitors increase ACE2 expression in animal models 
and humans. Since ACE2 is the receptor for SARS-CoV2 it has been suggested that in 
patients treated with those drugs, the increase in the receptor may result in increased 
infection and therefore exacerbation of disease. Whether these treatments should be 
abandoned in favour of drugs neutral to ACE2, such as calcium channel blockers, is under 
discussion (5). However, there is at present no definitive evidence in humans in favour of 
this suggestion.  
 
On the other hand, the protective effect of ACE2 over-expression is better understood and 
has led to the contrasting hypothesis that using ARB might protect against viral induced 
lung injury. In a model of SARS-CoV infection, the blockade of AT1 receptors revealed 
itself effective in attenuating pulmonary oedema and severe lung injury (3). In addition 
to attenuating the binding of Ang II to its AT1 receptors, the beneficial actions of ARB 
may be explained by two possible mechanisms: 1) the restored ACE2, normally decreased 
during the viral infection, helps reducing the concentrations of Ang II (3) and, 2) there is 
an increased generation of the protective Ang-(1-7). 
 
More clinical and experimental evidence is required to resolve this controversy. 
Meanwhile, we would like to suggest that during viral infection increasing the Ang-(1-7) 
concentration might be vital for protecting from endothelial cell activation and lung 
damage. The use of Ang-(1-7) or one of its mimetics should be considered among other 
strategies to prevent damage in high risk patients. 
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Figure 1. Diagram representing the main metabolic pathways driven by angiotensin-
converting enzyme (ACE) and angiotensin-converting enzyme-2 (ACE2) in the renin-
angiotensin system. The pharmacological targets for ACE inhibitors (ACEI) and 
angiotensin AT1 receptors blockers (ARB) are also shown. Ang, angiotensin.  
 
